With one kinase inhibitor in the clinic and two more in the queue, Ambit Biosciences Corp. raised $49.3 million in a Series D financing round. (BioWorld Today)

LSD Deal Brings Amicus $50M Now, $390M Later

Nov. 14, 2007

By Trista Morrison

LSD Deal Brings Amicus $50M Now, $390M Later

Nov. 14, 2007

By Trista Morrison

Ambit's Series D Raises $50M For Kinase Inhibitor Program

Nov. 14, 2007

By Trista Morrison

With one kinase inhibitor in the clinic and two more in the queue, Ambit Biosciences Corp. raised $49.3 million in a Series D financing round. (BioWorld Today)

Synta's Elesclomol In Pivotal Study In Melanoma Patients

Nov. 13, 2007

By Trista Morrison

A month after signing a billion-dollar deal with GlaxoSmithKline plc for elesclomol (formerly STA-4783), Synta Pharmaceuticals Corp. kicked off a pivotal Phase III trial of the drug in metastatic melanoma. (BioWorld Today)

Today's news in brief
BioWorld
BioWorld briefs for Feb. 9, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...